docetaxel and vinorelbine plus filgrastim in treating patients with stage iiib or stage iv non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. purpose: phase ii trial to study the effectiveness of combination chemotherapy plus filgrastim in treating patients who have stage iiib or stage iv non-small cell lung cancer.

objectives: i. determine the response to docetaxel and vinorelbine with filgrastim (g-csf) support in patients with stage iiib or iv non-small cell lung cancer. ii. determine the toxicity of this regimen in these patients. iii. determine the overall survival and time to tumor progression in patients treated with this regimen. outline: this is a multicenter study. patients receive vinorelbine iv over 6-10 minutes and docetaxel iv over 1 hour on day 1 and filgrastim (g-csf) subcutaneously daily on days 2-12 or until blood counts recover. treatment continues every 2 weeks in the absence of disease progression or unacceptable toxicity. patients are followed every 3 months. projected accrual: a total of 60 patients will be accrued for this study within 1 year.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed stage iiib or iv non-small cell lung cancer bidimensionally measurable or evaluable disease no symptomatic brain metastases patient characteristics: age: over 18 performance status: karnofsky 70-100% life expectancy: greater than 2 months hematopoietic: absolute neutrophil count at least 2,000/mm3 platelet count at least 100,000/mm3 hepatic: ast and alt no greater than 1.5 times upper limit of normal (uln) bilirubin no greater than uln renal: creatinine no greater than 2.0 mg/dl cardiovascular: no uncontrolled hypertension, unstable angina, congestive heart failure, or atrial or ventricular arrhythmias at least 6 months since prior myocardial infarction other: not pregnant or nursing negative pregnancy test fertile patients must use effective contraception hiv negative no poorly controlled diabetes no known allergy to e. coli derivatives or any products to be administered no other prior malignancy within the past 5 years except surgically cured basal cell skin cancer or carcinoma in situ of the cervix no active infection or fever not previously entered in this study prior concurrent therapy: biologic therapy: no other concurrent hematopoietic growth factors chemotherapy: no prior chemotherapy endocrine therapy: not specified radiotherapy: at least 2 weeks since prior radiotherapy and recovered surgery: at least 2 weeks since prior major thoracic or abdominal surgery and recovered at least 6 months since prior coronary angioplasty other: at least 30 days since prior investigational agents no other concurrent investigational agent no prophylactic acetaminophen for fever

Keywords: stage iiib non-small cell lung cancer stage iv non-small cell lung cancer